Skip to main content

Table 3 Baseline characteristics of patients in each enrolled trial

From: Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

Author (year) No.a Age (year, SD)a Sex (Male, %)a BMI (kg/m2, SD)a Smoking (Pack-year, SD)a Post-FEV1/FVC (%, SD)a Post-FEV1 (L, SD)a Post-FEV1 (%predicted, SD)a Post-FVC (L, SD)a
Bredenbroker, 2002 169 NM NM NM NM NM NM NM NM
Boszormenyi-Nagy, 2005 200 NM NM NM NM NM NM NM NM
Rabe, 2005 555 64 (42 ~ 87) 410 (75) 26 (5.0) 41 (20.6) 50 (12) 1.50 (0.48) 54 (13.2) 3.08 (0.85)
Calverley, 2007 760 65 (9.6) 571 (75) 25 (5.0) 42 (22.9) 40.3 (11.2) 1.13 (0.04) 41 (11.0) NM
Calverley, 2009 1537 64 (9) 1150 (75) 25.8 (5.9) 48 (25) 42.3 (11.2) 1.10 (0.4) 36.1 (10.6) NM
Fabbri, 2009 M2-127 466 65 (9) 319 (68) NM 43 (22) 49.8 (9.4) 1.51 (0.4) 54.7 (9.1) NM
M2-128 371 64 (9) 262 (71) NM 43 (22) 52.7 (10.3) 1.55 (0.5) 56.0 (11.6) NM
Lee, 2011 203 68 (41 ~ 91) 188 (92.6) 22.39 (3.7) 42 (22.1) 50.5 (11.8) 1.41 (0.5) 55.1 (16.5) NM
Rennard, 2011 (M2-111) 567 64 (8.7) 387 (68.3) 26.0 (5.7) 50 (28.2) 43.3 (10.1) 1.12 (0.4) 36.8 (10.7) NM
Ferguson, 2012 1150 NM NM NM NM NM NM NM NM
O’Donnell, 2012 127 60 (9) 93 (73.2) 26.4 (5.0) 41 (20) 51 (11) NM 56 (12) NM
Zheng, 2014 313 64.2 (8.76) 283 (90.4) 21.8 (3.42) 37.2 (21.18) 35.78 (9.69) 0.95 (0.35) 36.84 (11.42) NM
Martinez, 2015 969 65 (8.4) 718 (74) 26.5 (5.47) 48 (24.6) 40.2 (10.81) 1.1 (0.33) 35.4 (9.25) NM
Wells, 2015 11 62 (7) 7 (64) NM 47 (26) 53 (12) NM 45 (12) NM
  1. aData reported in all patients receiving vitamin D supplementation
  2. BMI body mass index, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, NM not mentioned, No. numbers, SD standard derivation